{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:09:51Z","timestamp":1784408991258,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,28]]},"DOI":"10.7759\/cureus.84962","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T12:40:13Z","timestamp":1748436013000},"source":"Crossref","is-referenced-by-count":1,"title":["Clear Cell Renal Cell Carcinoma With Brain Metastases Treated With Complementary Ketogenic Metabolic Therapy: A Case Report"],"prefix":"10.7759","author":[{"given":"Alfredo","family":"Acevedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zapata Laguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Global Cancer Observatory. Cancer today. (2024). Accessed. May 7, 2024: http:\/\/gco.iarc.who.int\/today."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.12848","article-title":"Renal cell carcinoma: a review","volume":"332","author":"Rose TL","year":"2024","unstructured":"Rose TL, Kim WY. Renal cell carcinoma: a review. JAMA. 2024, 332:1001-10. 10.1001\/jama.2024.12848","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer RJ","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, et al.. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018, 378:1277-90. 10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini BI","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, et al.. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019, 380:1116-27. 10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer R","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, et al.. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021, 384:1289-300. 10.1056\/NEJMoa2035716","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri TK","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, et al.. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021, 384:829-41. 10.1056\/NEJMoa2026982","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212851","article-title":"Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma","volume":"388","author":"Choueiri TK","year":"2023","unstructured":"Choueiri TK, Powles T, Albiges L, et al.. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. N Engl J Med. 2023, 388:1767-78. 10.1056\/NEJMoa2212851","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003844","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b\/4 CheckMate 920 trial","volume":"10","author":"Tykodi SS","year":"2022","unstructured":"Tykodi SS, Gordan LN, Alter RS, et al.. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b\/4 CheckMate 920 trial. J Immunother Cancer. 2022, 10:e003844. 10.1136\/jitc-2021-003844","journal-title":"J Immunother Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601269","article-title":"Role of glucose and ketone bodies in the metabolic control of experimental brain cancer","volume":"89","author":"Seyfried TN","year":"2003","unstructured":"Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer. 2003, 89:1375-82. 10.1038\/sj.bjc.6601269","journal-title":"Br J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2018.00020","article-title":"Management of glioblastoma multiforme in a patient treated with ketogenic metabolic therapy and modified standard of care: a 24-month follow-up","volume":"5","author":"Elsakka AM","year":"2018","unstructured":"Elsakka AM, Bary MA, Abdelzaher E, Elnaggar M, Kalamian M, Mukherjee P, Seyfried TN. Management of glioblastoma multiforme in a patient treated with ketogenic metabolic therapy and modified standard of care: a 24-month follow-up. Front Nutr. 2018, 5:20. 10.3389\/fnut.2018.00020","journal-title":"Front Nutr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27603","article-title":"Restricted ketogenic diet therapy for primary lung cancer with metastasis to the brain: a case report","volume":"14","author":"Evangeliou AE","year":"2022","unstructured":"Evangeliou AE, Spilioti MG, Vassilakou D, Goutsaridou F, Seyfried TN. Restricted ketogenic diet therapy for primary lung cancer with metastasis to the brain: a case report. Cureus. 2022, 14:e27603. 10.7759\/cureus.27603","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jhn.12587","article-title":"A systematic review of the use of ketogenic diets in adult patients with cancer","volume":"31","author":"Sremanakova J","year":"2018","unstructured":"Sremanakova J, Sowerbutts AM, Burden S. A systematic review of the use of ketogenic diets in adult patients with cancer. J Hum Nutr Diet. 2018, 31:793-802. 10.1111\/jhn.12587","journal-title":"J Hum Nutr Diet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/1743-7075-8-54","article-title":"Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial","volume":"8","author":"Schmidt M","year":"2011","unstructured":"Schmidt M, Pfetzer N, Schwab M, Strauss I, K\u00e4mmerer U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial. Nutr Metab (Lond). 2011, 8:54. 10.1186\/1743-7075-8-54","journal-title":"Nutr Metab (Lond)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12986-016-0113-y","article-title":"Modified Atkins diet in advanced malignancies - final results of a safety and feasibility trial within the Veterans Affairs Pittsburgh Healthcare System","volume":"13","author":"Tan-Shalaby JL","year":"2016","unstructured":"Tan-Shalaby JL, Carrick J, Edinger K, Genovese D, Liman AD, Passero VA, Shah RB. Modified Atkins diet in advanced malignancies - final results of a safety and feasibility trial within the Veterans Affairs Pittsburgh Healthcare System. Nutr Metab (Lond). 2016, 13:52. 10.1186\/s12986-016-0113-y","journal-title":"Nutr Metab (Lond)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2337-7","article-title":"Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet","volume":"16","author":"Lussier DM","year":"2016","unstructured":"Lussier DM, Woolf EC, Johnson JL, Brooks KS, Blattman JN, Scheck AC. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet. BMC Cancer. 2016, 16:310. 10.1186\/s12885-016-2337-7","journal-title":"BMC Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1344891","article-title":"Ketogenic diet enhances the anti-cancer effects of PD-L1 blockade in renal cell carcinoma","volume":"15","author":"Richard J","year":"2024","unstructured":"Richard J, Beauvillain C, Benoit M, et al.. Ketogenic diet enhances the anti-cancer effects of PD-L1 blockade in renal cell carcinoma. Front Endocrinol (Lausanne). 2024, 15:1344891. 10.3389\/fendo.2024.1344891","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref17","unstructured":"ClinicalTrials.gov. A pilot study evaluating a ketogenic diet concomitant to nivolumab and ipilimumab in patients with metastatic renal cell carcinoma (KETOREIN). (2024). Accessed. April 21, 2025: https:\/\/clinicaltrials.gov\/study\/NCT05119010."},{"key":"ref18","unstructured":"ClinicalTrial.gov. Ketogenic diet for patients receiving treatment for metastatic renal cell carcinoma (CETOREIN). (2024). Accessed. April 21, 2025: http:\/\/clinicaltrials.gov\/study\/NCT04316520."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/340526-clear-cell-renal-cell-carcinoma-with-brain-metastases-treated-with-complementary-ketogenic-metabolic-therapy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T12:40:15Z","timestamp":1748436015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/340526-clear-cell-renal-cell-carcinoma-with-brain-metastases-treated-with-complementary-ketogenic-metabolic-therapy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.84962","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,28]]}}}